For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Otonomy, Inc.

USPTO Granted Patents = 42

CIPO Patents = 4

EPO Patents = 3

Trademarks = 2

Forward Citations = 483

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Fabrice Piu (37 out of 43 patents)

Carl Lebel (35 out of 37 patents)

Qiang Ye (34 out of 42 patents)

4. Luis A Dellamary (34 out of 74 patents)

5. Jay Lichter (33 out of 38 patents)

6. Andrew M Trammel (33 out of 35 patents)

7. Jeffrey P Harris (32 out of 35 patents)

8. Benedikt K Vollrath (13 out of 25 patents)

9. Michael Christopher Scaife (12 out of 13 patents)

10. Sergio G Duron (9 out of 17 patents)

11. Scott H Coleman (3 out of 5 patents)

12. Robert Savel (3 out of 5 patents)

13. Sergio G Durón (3 out of 8 patents)

14. Wei-Cheng Liaw (2 out of 4 patents)

15. Jerry Wroblewski (2 out of 3 patents)

Core Competencies:

Otic Disorders

CNS Modulating Compositions

Controlled Release Formulations

Antimicrobial Compositions

Corticosteroid Treatments

Auris Formulations

Trk B Antagonists

Trk C Antagonists

Sensory Cell Modulators

Aural Pressure Modulators

Pediatric Otic Treatments

Free-Radical Damage Modulation

42 patents: Sort by Forward Citations

1. 11123286 - Auris formulations for treating otic diseases and conditions (2021-09-21),

2. 11123285 - Auris formulations for treating OTIC diseases and conditions (2021-09-21),

3. 11040004 - Otic gel formulations for treating otitis externa (2021-06-22),

4. 11034961 - Treatment using truncated Trk B and Trk C antagonists (2021-06-15),

5. 10918594 - Controlled-release CNS modulating compositions and methods for the treatment of otic disorders (2021-02-16),

6. 10821185 - Triglyceride otic formulations and uses thereof (2020-11-03),

7. 10772828 - Controlled release antimicrobial compositions and methods for the treatment of otic disorders (2020-09-15),

8. 10751281 - Auris formulations for treating otic diseases and conditions (2020-08-25),

9. 10272034 - Auris formulations for treating otic diseases and conditions (2019-04-30),

10. 10232044 - Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders (2019-03-19),

11. 10092580 - Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders (2018-10-09),

12. 10066229 - Treatment using truncated Trk B and Trk C antagonists (2018-09-04),

13. 9867778 - Controlled release antimicrobial compositions and methods for the treatment of otic disorders (2018-01-16),

14. 9808460 - Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders (2017-11-07),

15. 9757484 - Sterilization of ciprofloxacin composition (2017-09-12),

Otonomy, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutics for otology. The company's mission is to improve the lives of patients with diseases of the ear by providing novel treatments. Otonomy's pipeline includes products targeting various ear-related conditions, such as hearing loss, tinnitus, and middle ear infections. Through its research and development efforts, the company aims to address significant unmet medical needs in the field of otology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

42 Patents

#138 in San Diego, CA

#1,883 in California

#7,985 in US

#15,864 in the World

San Diego, CA, United States of America

Otonomy, Inc.

Forward Citations = 483

20 inventors:

Fabrice Piu (37 out of 43 patents)

Carl Lebel (35 out of 37 patents)

Qiang Ye (34 out of 42 patents)

4. Luis A Dellamary (34 out of 74 patents)

5. Jay Lichter (33 out of 38 patents)

Please report any incorrect information to support@idiyas.com

Loading…